Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Gilead Sciences stock

Learn how to easily invest in Gilead Sciences stock.

Gilead Sciences is a biopharmaceutical company headquartered in California. The company is most well-known as the maker of remdesivir, also known as Veklury, an experimental antiviral drug that may help treat the novel coronavirus.

In May, remdesivir was designated for emergency use authorization for treatment of COVID-19 by the U.S. Food and Drug Administration (FDA), which means it's being used to treat patients in emergency situations. While the drug isn't fully approved by the FDA and its efficacy and long-term effects are still being studied, this designation has generated a lot of buzz for Gilead.

How to buy shares in Gilead Sciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GILD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

How has COVID-19 affected Gilead’s stock price?

In March 2020, Gilead’s stock began to gain traction, leading to several notable price spikes in the spring and hitting a high of $83.99 in April 2020. But the stock began to fall off over the summer, experiencing a 25% decline it has yet to recover from as of October.

However, when President Trump received remdesivir as part of his COVID-19 treatment, Gilead’s stock rose 3% in the days that followed. How Gilead’s stock performs in the coming months will likely hinge on the efficacy of its experimental treatments.

What is remdesivir?

Remdesivir, sold under the brand name Veklury, is an antiviral medication — specifically, an investigational nucleotide analog designed to reduce viral activity in a variety of illnesses, including Ebola, SARS, Marburg, MERS and SARS-CoV-2 — the virus responsible for COVID-19.

Remdesivir is currently in international Phase 3 trials. Based on initial trial data, the medication has been approved by the FDA for Emergency Use Authorization in the treatment of patients hospitalized with COVID-19. But this authorization is temporary, may be revoked at any time and doesn’t guarantee the drug will officially pass the FDA’s submission, review and approval process.

Gilead Sciences stock price (NASDAQ: GILD)

Use our graph to track the performance of GILD stocks over time.

Gilead Sciences shares at a glance

Information last updated 2022-10-04.
Latest market close$62.32
52-week range$55.27 - $71.47
50-day moving average $63.34
200-day moving average $63.50
Wall St. target price$71.07
PE ratio 19.0581
Dividend yield $2.88 (4.73%)
Earnings per share (TTM) $3.27

Buy Gilead Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Gilead Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gilead Sciences price performance over time

Historical closes compared with the close of $62.32 from 2022-10-03

1 week (2022-09-27) -0.49%
1 month (2022-09-02) -2.35%
3 months (2022-07-01) -0.06%
6 months (2022-04-01) 4.44%
1 year (2021-10-04) -7.76%
2 years (2020-10-02) 0.24%
3 years (2019-10-04) 62.56
5 years (2017-10-04) 82.42

Is Gilead Sciences stock undervalued or overvalued?

Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Gilead Sciences's P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Gilead Sciences shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Gilead Sciences's PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5376. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Gilead Sciences's EBITDA

Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.2 billion.

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.

Gilead Sciences financials

Revenue TTM $27.5 billion
Operating margin TTM 40.36%
Gross profit TTM $21.8 billion
Return on assets TTM 10.61%
Return on equity TTM 20.58%
Profit margin 15.04%
Book value $16.14
Market capitalisation $78.1 billion

TTM: trailing 12 months

Gilead Sciences's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Gilead Sciences's total ESG risk score

Total ESG risk: 22.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 01/01/2019) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Gilead Sciences's environmental score

Environmental score: 0.53/100

Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Gilead Sciences's social score

Social score: 12.97/100

Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Gilead Sciences's governance score

Governance score: 7.65/100

Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Gilead Sciences's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Gilead Sciences Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.15
Total ESG percentile 30.98
Environmental score 0.53
Environmental score percentile 2
Social score 12.97
Social score percentile 2
Governance score 7.65
Governance score percentile 2
Level of controversy 2

Gilead Sciences share dividends

41%

Dividend payout ratio: 41.19% of net profits

Recently Gilead Sciences has paid out, on average, around 41.19% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.73% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 4.73% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.88 per share.

While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.

Gilead Sciences's most recent dividend payout was on 29 September 2022. The latest dividend was paid out to all shareholders who bought their shares by 14 September 2022 (the "ex-dividend date").

Have Gilead Sciences's shares ever split?

Gilead Sciences's shares were split on a 2:1 basis on 28 January 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.

Gilead Sciences share price volatility

Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $55.2732 up to $71.4734. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.328. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).

Gilead Sciences overview

Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.

Frequently asked questions

What percentage of Gilead Sciences is owned by insiders or institutions?
Currently 0.092% of Gilead Sciences shares are held by insiders and 82.015% by institutions.
How many people work for Gilead Sciences?
Latest data suggests 14,400 work at Gilead Sciences.
When does the fiscal year end for Gilead Sciences?
Gilead Sciences's fiscal year ends in December.
Where is Gilead Sciences based?
Gilead Sciences's address is: 333 Lakeside Drive, Foster City, CA, United States, 94404
What is Gilead Sciences's ISIN number?
Gilead Sciences's international securities identification number is: US3755581036
What is Gilead Sciences's CUSIP number?
Gilead Sciences's Committee on Uniform Securities Identification Procedures number is: 375558103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site